Serum osteoprotegerin concentration with strontium ranelate treatment for postmenopausal osteoporosis: An open prospective study

Ertorer M. E. , Bakiner O., Anaforoglu I., Sezgin N. , Dernirag N. G. , Tutuncu N. B.

CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, vol.68, no.4, pp.217-225, 2007 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 68 Issue: 4
  • Publication Date: 2007
  • Doi Number: 10.1016/j.curtheres.2007.08.001
  • Title of Journal : CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
  • Page Numbers: pp.217-225

Abstract

Background: Strontium ranelate (SR) is a new antiosteoporotic agent with antiresorptive and bone-forming properties. The exact mechanism by which SR exerts its effects is not clearly understood. Bone resorption requires interaction between osteoblasts and osteoclasts. Osteoblasts produce a ligand for receptor activator of nuclear factor-kappa B (RANK). They also secrete osteoprotegerin, a decoy protein that blocks the interaction of RANK with its ligand, thereby inhibiting the differentiation and activity of osteoclasts. SR also has been associated with osteoblast proliferation and decreased osteoblast-induced osteoclast differentiation via increased osteoprotegerin messenger RNA expression in human osteoblasts.